Parallax Volatility Advisers
BBIO icon

Parallax Volatility Advisers’s BridgeBio Pharma BBIO Stock Holding History

Parallax Volatility Advisers’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-109,700
Closed -$3.79M – 1560
2025
Q1 		$3.79M Buy
109,700
+29,000
+36% +$978K 0.01% 693
2024
Q4 		$2.21M Buy
+80,700
New +$2.09M ﹤0.01% 1109
2024
Q1 		– Sell
-309,200
Closed -$12.5M – 1835
2023
Q4 		$12.5M Buy
309,200
+265,300
+604% +$7.97M 0.03% 528
2023
Q3 		$1.16M Buy
43,900
+29,000
+195% +$823K ﹤0.01% 1301
2023
Q2 		$256K Buy
+14,900
New +$224K ﹤0.01% 1828

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parallax Volatility Advisers's BBIO Position: Q1 2026 in Review

Parallax Volatility Advisers sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 5,538 shares — an estimated $424K sold.

Parallax Volatility Advisers first reported a position in BBIO in Q1 2023 and held it in 6 quarters. The position peaked at $429K in Q4 2024. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Parallax Volatility Advisers reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
  • Parallax Volatility Advisers sold 5,538 BridgeBio Pharma shares in Q1 2026, an estimated $424K.
  • Parallax Volatility Advisers first reported a position in BridgeBio Pharma in Q1 2023 and held it in 6 quarters.
  • Parallax Volatility Advisers's BridgeBio Pharma position peaked at $429K in Q4 2024.
  • 458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Parallax Volatility Advisers's 13F filing for Q1 2026, filed 15 May 2026.